Catalyst

Slingshot members are tracking this event:

FDA Places Hold on Teva (TEVA) and Regeneron's (REGN) Phase 2b Trial Evaluating Fasinumab in Chronic Low Back Pain

Source Link:
http://files.shareholder.com/downloads/REGN/2835364741x0x911955/07DE27F6-253D-44EE-95D9-043E5C1EBC34/REGN_News_2016_10_17_General_Releases.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TEVA
100%
REGN
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 17, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Clinical Hold, Fda, Phase 2b Centaur, Fasinumab, Chronic Low Back Pain
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.